Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients

摘要: Dihydropyrimidine dehydrogenase (DPD) is the first and rate limiting enzyme in catabolism of 5-fluorouracil (5-FU). It has been reported from various laboratories that plasma concentration 5-FU was influenced by DPD activities normal human organs (e.g. liver or lymphocytes). Since congenital deficiency caused severe, some cases lethal, FU-related toxicity, it decided to collect data about activity colorectal cancer patients order investigate possible correlation between appearance side effects 5-FU. Assuming lymphocytes represents catabolic capacity organism, determined 48 with after surgery during therapeutic course folinic acid. On basis activity, were divided into three categories: low (DPD 6 lymphocytes); medium = 5.04–13.25 pmol/min/106 lymphocytes), high > 13.26 lymphocytes) groups. By evaluating toxic + acid treatment, following results obtained. In group, 9 11 had 5-FU-related (mucositis, diarrhea, myelotoxicity, angina pectoris, hypertension). 3 patients, no change therapy needed, symptoms could be reversed dose reduction while interruption needed. mild toxicity (diarrhea, transitory hypertension) occurred 5 29 group (diarrhea) 1 8 respectively. these last two groups, necessary. The present study furnished further evidence for function. Consequently, recommended measure prior based chemotherapy, which might helpful avoiding drug-related adjusting individually.